RenovoRx Announces $11.1 Million At Market Private Placement Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial thr

Announces $11.1 Million At Market Private Placement

ALTOS, CA - April 8, 2024 - RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage

biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the

execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross

proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.

proceeds from this financing, in addition to RenovoRx's previously announced private placement on January 29, 2024 for gross proceeds

of approximately $6.1 million, extend the Company's cash runway into 2026. The financing allows RenovoRx to advance its lead program,

the pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), through the second interim readout and towards

completion of the trial. The TIGeR-PaC study is an ongoing randomized multi-center study in LAPC using RenovoRx's proprietary TAMP

(Trans-Arterial Micro-Perfusion) therapy platform to evaluate its first product candidate, RenovoGem , a

novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care (systemic

intravenous chemotherapy). RenovoRx expects that the second interim analysis for this study will be triggered by the 52nd event in the

trial, which is estimated to occur in late 2024.

from the financing are also expected to enable the expansion of the TAMP clinical development pipeline into additional cancer indications.

definite subscription agreements were executed based on the closing price of RenovoRx's common stock on April 4, 2024, and the

private placement is expected to close on April 11, 2024, subject to customary closing conditions. Newbridge Securities Corporation is

acting as sole placement agent for the transaction.

of the Private Placement

connection with the private placement, the Company will issue 7,912,364 shares of common stock, five-year Series A Warrants to purchase

an aggregate of up to 7,912,364 shares of common stock, and two-year Series B Warrants, to purchase an aggregate of up to 3,956,182 shares

of common stock, with the Series A Warrants and Series B Warrants together constituting 150% warrant coverage. Investors will pay a purchase

price of $1.4075 for each share and associated Series A Warrant and Series B Warrant, with such price being at the market for purposes

of Nasdaq Stock Market rules. The Series A Warrants and Series B Warrants are each exercisable for $1.22 per share. The Series B Warrants

are callable by the Company after 6 months if certain price and volume thresholds are achieved.

securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities

laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration

requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares and the shares underlying

the Series A Warrants and Series B Warrants issuable in connection with the private placement.

press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale

of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification

under the securities laws of any such jurisdiction.

is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with

a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion

(TAMPTM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially

minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel and patented approach to targeted

treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGemTM,

a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated

by the FDA's 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer

by the Center for Drug Evaluation and Research (the drug division of FDA.)

is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care.

RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.

Note Regarding Forward-Looking Statements

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of

the Securities Exchange Act of 1934, including but not limited to statements regarding (i) the anticipated closing and use of proceeds

from the private placement described herein and (ii) our clinical trials and studies, including anticipated timing, statements regarding

the potential of RenovoCath , RenovoGem or TAMP or regarding our ongoing TIGeR-PaC Phase III clinical trial study in

LAPC, and (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions

or diseases. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein

are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain,

outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates,

projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, financing

plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and

unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these

forward-looking statements. These statements may be identified using words such as "will," "may," "expects,"

"plans," "aims," "anticipates," "believes," "forecasts," "estimates,"

"intends," and "potential," or the negative of these terms or other comparable terminology regarding RenovoRx's

expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements

are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected

or indicated by such statements, including, among other things: (i) circumstances which would adversely impact our ability to efficiently

utilize the net proceeds of the private placement described herein, (ii) the timing of the initiation, progress and potential results

(including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iii) the possibility

that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy

to support regulatory approval of our product candidate, (iv) that the applicable regulatory authorities may disagree with our interpretation

of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (v) future

potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vi) our

ability to use and expand our therapy platform to build a pipeline of product candidates; (vii) our ability to advance product candidates

into, and successfully complete, clinical trials; (viii) the timing or likelihood of regulatory filings and approvals; (ix) our estimates

of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials;

(x) the commercialization potential of our product candidates, if approved; (xi) our ability and the potential to successfully manufacture

and supply our product candidates for clinical trials and for commercial use, if approved; (xii) future strategic arrangements and/or

collaborations and the potential benefits of such arrangements; (xiii) our estimates regarding expenses, future revenue, capital requirements

and needs for additional financing and our ability to obtain additional capital; (xiv) the sufficiency of our existing cash and cash

equivalents to fund our future operating expenses and capital expenditure requirements; (xv) our ability to retain the continued service

of our key personnel and to identify, and hire and retain additional qualified personnel; (xvi) the implementation of our strategic plans

for our business and product candidates; (xvii) the scope of protection we are able to establish and maintain for intellectual property

rights, including our therapy platform, product candidates and research programs; (xviii) our ability to contract with third-party suppliers

and manufacturers and their ability to perform adequately; (xix) the pricing, coverage and reimbursement of our product candidates, if

approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information

regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that we file

from time to time with the Securities and Exchange Commission.

statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking

statements to reflect subsequent events or circumstances, except as required by law.

Strategic Communications

Pinto, Managing Director